Intrathecal administration: Difference between revisions

Content deleted Content added
Intrathecal administration of analgesic agents: merge "main articles" into a "see also" template
Line 28:
 
==Intrathecal chemotherapy==
*Currently, only four agents are licensed for intrathecal chemotherapy:
**They are [[methotrexateMethotrexate]], [[cytarabine]] (Ara-C), [[hydrocortisone]], and, rarely, [[thiotepa]].<ref name="pmid8445432">{{cite journal |vauthors=Grossman SA, Finklestein DM, Ruckdeschel JC, etal | title = Randomized prospective comparison of intraventricular methotrexate and thiotepa with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. | journal = Journal of Clinical Oncology | volume = 11 | issue = 3 | pages = 561–9 |date=March 1993 | pmid = 8445432 | doi=10.1200/jco.1993.11.3.561}}</ref>
*Accidental administration of any [[vinca alkaloid]]s—especially [[vincristine]] but also vinblastine, vinorelbine, or others—via the intrathecal route is nearly always fatal.<ref name="pmid15378106">{{cite journal | author = Schulmeister L | title = Preventing vincristine sulfate medication errors | journal = Oncology Nursing Forum | volume = 31 | issue = 5 | pages = E90–8 |date=September 2004 | pmid = 15378106 | doi = 10.1188/04.ONF.E90-E98 | doi-access = free }}</ref><ref name="pmid17355029">{{cite journal |vauthors=Qweider M, Gilsbach JM, Rohde V | title = Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report | journal = Journal of Neurosurgery. Spine | volume = 6 | issue = 3 | pages = 280–3 |date=March 2007 | pmid = 17355029 | doi = 10.3171/spi.2007.6.3.280 }}</ref><ref name="IMSN-gTMSBP">{{Citation |author=International Medication Safety Network |year=2019 |title=IMSN Global Targeted Medication Safety Best Practices |url=https://www.intmedsafe.net/imsn-global-targeted-medication-safety-best-practices/ |access-date=2020-03-11 |postscript=.}}</ref>